Gemcitabine hydrochloride is a new type of artificially synthesized difluoronucleoside antimetabolite antitumor drug, developed by Eli Lilly and Company. FDA for short) approved clinical use for the first-line treatment of non-small cell lung cancer and pancreatic cancer.
As a prodrug, gemcitabine hydrochloride is a good substrate for deoxythymidine kinase phosphorylation in cells and can be converted into the following metabolites under the action of enzymes: gemcitabine-phosphate (dFdCMP), gemcitabine diphosphate (dFdCDP) and Gemcitabine triphosphate (dFdCTP), of which the latter two are the active products. In recent years, new drugs such as gemcitabine, paclitaxel, docetaxel, isovinblastine, etc. are effective drugs for the treatment of non-small cell lung cancer (NSCLC) by Chemicalbook. Compared with traditional chemotherapy drugs, they have high efficacy and low toxicity. advantage. Gemcitabine hydrochloride is a new-generation antimetabolite, a cell cycle-specific drug, which mainly acts on cells in the DNA synthesis phase, that is, S phase cells. Under certain conditions, it can also prevent the progression from G1 phase to S phase, and it has strong anticancer activity against non-small cell lung cancer (NSCLC). Foreign studies have shown that the effective rate of gemcitabine hydrochloride alone in the treatment of NSCLC is 18% to 35%. The effective rate of combined cisplatin in the treatment of non-small cell lung cancer (NSCLC) was 41.7%. The effective rate of carboplatin for advanced NSCLC is 16%, and the efficacy is similar to that of cisplatin, but the toxicity is low, especially the gastrointestinal reaction, bone marrow suppression, kidney and peripheral nerve toxicity. Combined with carboplatin, it has mutual coordination and additive effects, and can produce higher curative effect.
){kind=link}